



NUCLEA
BIOTECHNOLOGIES

PRESS RELEASE

For Immediate Release:
January 11, 2012

Contact: Patrick J. Muraca
Office: 413.749.4705

Nuclea Biotechnologies Submits Pre-Market IDE Filings on Fatty Acid Synthase Assays for FDA Regulatory Review

Pittsfield, MA -- Biomarker pioneer Nuclea Biotechnologies, Inc. today announced that the company has filed Pre-Market IDE regulatory filings for FDA review on its Fatty Acid Synthase (FAS) and USP2a diagnostic assays in both Breast and Prostate cancer.

The Pre-market filings were submitted for review by the FDA beginning in mid 2011 outlining the use of FAS as a monitoring tool in prostate cancer and in breast cancer.

“This is a major achievement for Nuclea and the way prostate cancer and breast cancer will be managed in the future,” said Patrick J. Muraca, president & CEO of Nuclea Biotechnologies, Inc. “Nuclea is committed to advancing these pre-market filings forward with the highest clinical quality and setting new standards in personalized medicine for the management of disease”

Nuclea Biotechnologies, Inc. is headquartered in Pittsfield, Massachusetts. Nuclea has three lines of business, each of which is operated by a separate wholly-owned subsidiary: Nuclea Diagnostic Laboratories (“NDL”) which has developed and is commercializing unique diagnostic tests for colon, breast, leukemia, lung and prostate cancer; Nuclea Biomarkers (“NBM”) which performs research leading to novel molecular oncology therapeutics and diagnostics for the pharmaceutical and biotechnology industries and performs services by analyzing and testing the efficacy and validating other indications of existing therapeutics utilizing a highly characterized and consented patient database; and Nuclea Biotherapeutics (“NBT”) which develops novel therapeutics.